Find and Pitch Jounalists, Get Your Story Covered

Tags: dreams sleep REMS Training Documentation

	Profile	Recent Articles on Subject
1	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis - 6 days ago Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD - 7 days ago FDA Grants Orphan Drug, Fast Track Designation to RLS-0071 for aGVHD - about 1 month ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 10 months ago
2	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - 6 days ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - 12 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 days ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - 6 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - 7 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - 10 months ago STAT+: Pharmalittle: Eisai reports injectable version of Alzheimer’s drug as effective as IV; Pfizer says combo flu and Covid shot shows strong response - 11 months ago STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug - 11 months ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - 12 months ago
4	John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. Healthcare journalism	Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus - 15 days ago Everything (Maybe) You Wanted to Know About Sarilumab for PMR - 12 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 29 days ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 6 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 6 months ago STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show - 11 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi - 29 days ago STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients - 11 months ago STAT+: European regulators consider appeal over Amylyx ALS drug - 11 months ago
7	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - about 1 month ago FDA Approves Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder - 6 months ago FDA Grants Breakthrough Device Designation for Neuroimmune Modulation Platform To Treat MS - 6 months ago Researchers Compare Reimbursement and Access to New Treatments in European Lung Cancer Care - 7 months ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - about 1 month ago A potential MS ‘game changer’ could bring more safety to the table — even against viruses - about 1 month ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - 6 months ago
9	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies - about 2 months ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - 6 months ago A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu - 7 months ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - 10 months ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - 11 months ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - 11 months ago
10	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago A Novel Mechanism of Action in Treating Relapsing MS - 10 months ago New Data on CD40 Ligand Inhibitor for Relapsing MS - 10 months ago Targeting Chronic Inflammation in Progressive MS - 10 months ago Multiple Sclerosis: Treat Early With High-Efficacy Therapy - 11 months ago Multiple Sclerosis: Paving the Way to a Cure - 11 months ago MS Treatment-Discontinuation Study Terminated After Disease Activity Returns - 11 months ago

Journalists covering REMS